Randomized Controlled Open Labelled, Phase III Trials, Comparing the Efficacy between Fentas(R) and Durogesic(R) Patches in Controlling Cancer Pain: Multicenter Trial

Myung‐Ju Ahn(Sungkyunkwan University), Hyonggi Jung, Jung Ae Lee, Mi Ran Oh, Chul Won Choi(Korea University), Sung Kyu Park, Jung Hye Choi(Hanyang University Guri Hospital), Jun Suk Kim, Dae Sik Hong, Hwi Joong Yoon, Tae June Jung, Young Suk Park(Seoul National University Bundang Hospital), Hee Sook Park, Kyung Wook Hur

Cancer Research and Treatment

June 30, 2002

10.4143/crt.2002.34.3.165

Cited by 0

Related Papers

Crizotinib versus Chemotherapy in Advanced <i>ALK</i> -Positive Lung Cancer

|New England Journal of Medicine|2013|3.4k

Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial

|The Lancet|2019|3.4k

Osimertinib or Platinum–Pemetrexed in <i>EGFR</i> T790M–Positive Lung Cancer

|New England Journal of Medicine|2016|3.3k

Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study

|The Lancet|2018|1.7k

Entrectinib in ROS1 fusion-positive non-small-cell lung cancer: integrated analysis of three phase 1–2 trials

|The Lancet Oncology|2019|537